Science1 publisher2 min readPublished
An earnout puts $700 million of Telix's price for ITM on meeting both regulatory and sales goals
Telix is buying privately held ITM in a merger STAT puts at a minimum of $1.65 billion, with another $700 million payable only if ITM's lead drug clears regulators and meets sales goals. STAT says the deal follows a surprise FDA rejection.
The Scientist · Science desk
What happened
- Telix Pharmaceuticals and ITM Isotope Technologies Munich are merging in a deal STAT values at a minimum of $1.65 billion.
- Telix could pay ITM shareholders a further $700 million if ITM's lead drug meets both regulatory and sales goals, according to STAT.
- Novartis, the company STAT says dominates this field, launched its two radiopharmaceutical treatments in 2018 and 2022.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- exposure ITM's shareholders keep regulatory risk after the deal closes, because about 30 percent of the maximum consideration only pays out if the lead drug is approved and then sells.
- cost Telix's final outlay is not set at signing; a regulator's decision and a commercial threshold determine whether the price ends at the floor or $700 million above it.
- constraint Nothing here establishes that rejections force radiopharma sellers to accept acquisition, and the reported material does not even establish whose drug was rejected.
Add the contingent payment to the floor price and the maximum consideration comes to about $2.35 billion [1], which puts roughly 30 percent of the top figure behind a condition that has not been satisfied [2]. Two separate events have to occur before that money moves: a regulator has to approve ITM's lead drug, and the drug has to hit sales goals [3]. STAT did not report either threshold. ITM is privately held, so Telix is buying the whole equity [2].
The products here deliver radioactive isotopes directly to cancer cells [7]. Novartis launched two of them, in 2018 and 2022 [8], four years apart [3], and STAT describes the field as currently dominated by that company [5]. The merger, in STAT's description, creates another well-resourced company in the same field [6].
STAT's headline places the merger after a surprise FDA rejection received by one of the two companies [4]. The excerpt does not name which company was rejected or for which drug [9]. An earnout keyed to a regulatory goal fits a buyer pricing an approval it cannot assume, and it also fits ordinary structure when the seller is private and its lead asset is unapproved. Both readings are consistent with the terms STAT reported [3].
Whether a clinical-stage radiopharmaceutical company can absorb a rejection alone, and whether consolidation is the expected result, are open questions here. Either one needs a denominator: how many clinical-stage companies in this field took a regulatory setback and stayed independent, and how many sold. One transaction does not supply it, and the reported material does not carry those counts.
On STAT's account the price is at least $1.65 billion firm [1], with about 30 percent of the maximum withheld against a decision that sits with a regulator [2].
What to watch
- Whether either company discloses which product drew the FDA rejection and what the agency asked for.
- Whether the regulatory and sales thresholds attached to the $700 million are published in deal filings.
- Whether the next clinical-stage radiopharmaceutical company to take a rejection stays independent or sells.